SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT02600260

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

Thromboprophylaxis in Pregnant Women in Hospital: A Prospective Clinical Trial

Hospitalization in pregnancy and childbirth greatly increases the thromboembolic risk of these patients. The application of a protocol for assessing the risk of VTE reduces mortality and morbidity of these phenomena.

NCT02600260 Thrombophilia Associated With Pregnancy Perioperative/Postoperative Complications Venous Thrombosis Pulmonary Embolism Other Specified Risk Factors in Pregnancy Deep Vein Thrombosis
MeSH: Thrombosis Embolism Pulmonary Embolism Venous Thrombosis Postoperative Complications Thrombophilia
HPO: Deep venous thrombosis Hypercoagulability Pulmonary embolism Venous thrombosis

2 Interventions

Name: Enoxaparin

Description: Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.

Type: Drug

enoxaparin

Name: No intervention

Description: Hospitalized patients that score less than three are not prescribed enoxaparin.

Type: Other

no intervention


Primary Outcomes

Description: Identify early risk factors for VTE in hospitalized pregnant women and prescribe appropriate prophylaxis to reduce the incidence, morbidity and mortality of VTE. The patients that score ≥ 3 will receive enoxaparin. This group will be analyzed for the incidence of adverse outcomes: VTE, bleeding, death until 3 months post hospitalization. This same analysis will be done in those patients who have not received heparin. The patients that could not receive heparin due to bleeding risk will be analyzed also. The analysis of the score will also describe if the higher the score, the higher the index of adverse events, mainly when it is not possible to prescribe the prophylaxis.

Measure: Number of hospitalized pregnant patients with venous thromboembolism (VTE), death and adverse events after applying an in hospital risk score for thrombosis at 12 weeks post discharge.

Time: 4 years

Purpose: Prevention

Allocation: Non-Randomized

Parallel Assignment


There is one SNP

SNPs


1 G20210A

Risk score description: score 3 - previous thrombosis/thromboembolism, homozygous mutations, combined thrombophilia risk factors, antiphospholipid syndrome, cancer(stomach, pancreas, lung), inflammatory conditions, lupus, sickle cell disease, nephrotic syndrome, heart disease; Score 2 - Protein C deficiency, Protein S deficiency, heterozygous F5 Leiden, heterozygous F2 G20210A mutation, cancer(last 6 months), chemotherapy(last 6m), immobility, bed rest >4d prior to C-section, current serious infections, BMI≥40 kg/m2 , age≥40y, lung disease(cyanosis), postpartum hemorrhage >1L; Score 1 - age ≥ 35 and ≤39 y, parity ≥3, multiple pregnancy, hyperemesis, gross varicose veins, smoker ≥20, surgical procedure. --- G20210A ---



HPO Nodes


HPO:
Deep venous thrombosis
Genes 12
THBD F2 PIEZO1 PROC F5 PROS1 SERPIND1 PMM2 SERPINC1 F9 AKT1 PLAT
Hypercoagulability
Genes 17
GATA2 AGGF1 MYD88 F5 HRG DLD F9 PLAT THBD SPTA1 EPB42 SPTB PROC SLC4A1 PROS1 PIGA ANK1
Pulmonary embolism
Genes 48
MPL IL10 CD55 JAK2 AGGF1 TET2 IL12A SERPINC1 CCR1 UBAC2 TRNF AKT1 C4A TRNH TRNL1 GNAQ TRNQ PIGA ACVRL1 TRNS1 TRNS2 COX1 PTEN COX2 GDF2 HLA-B COX3 TRNW FAS F2 ENG ERAP1 PLP1 CBS IL12A-AS1 KLRC4 KCNJ5 MEFV IL23R ND1 STAT4 PROC SMAD4 ND4 PROS1 TLR4 ND5 ND6
Venous thrombosis
Genes 74
MPL IL10 JAK2 TET2 IL12A EPOR MET PRSS1 USP8 PRSS2 SAA1 THBD PDE4D PRTN3 THPO HLA-B SPINK1 SH2B3 PDGFRA ERAP1 HLA-DPA1 CALR IL12A-AS1 HLA-DPB1 PIEZO1 CFTR TLR4 CTRC FGA CD55 FGB PRKAR1A AGGF1 CDH23 CPA1 SERPINC1 CASR CCR1 UBAC2 AKT1 PTPN22 PLAT C4A CTLA4 GNAQ IDH1 FGG IDH2 CTNNB1 ACVRL1 PTEN GDF2 FAS F2 HBB ENG F5 CBS SERPIND1 KLRC4 F9 PTH1R MEFV IL23R NOTCH1 PGM1 TP53 STAT4 KIF11 PROC SMAD4 PROS1 PMM2 PIGM